Live
- Aahwahan Foundation Launches “Sapnon Ke Sawari” Initiative to Empower Differently-Abled Individuals
- Are Market-linked Plans Suitable for First-time Investors?
- Vijay to host farmers, landowners who provided venue for TVK’s first meet in TN
- Bengal bypolls: Trinamool candidates declared elected from Naihati, Sitai; leading in other four seats too
- Black Friday 2024: Amazon, Samsung, Sony Discounts Unveiled; More Brands To Join
- UP bypolls: NDA leads in early trends, SP trails behind
- MVA stunned as MahaYuti heads to landslide win in Maharashtra polls
- Trends in Maha and J'khand a reflection of 'Modi magic': BJP
- Karnataka bypolls: Cong leading, celebrations in Channapatna; BJP concedes defeat in Sandur
- India-EFTA trade pact to drive $100 bn investment, boost 99.6 pc of exports
Alembic Pharma gets USFDA nod for insomnia treatment drug
Highlights
Drug firm Alembic Pharmaceuticals has received approval from the US health regulator for Temazepam capsules, used for treatment of insomnia
Drug firm Alembic Pharmaceuticals has received approval from the US health regulator for Temazepam capsules, used for treatment of insomnia.
The company has got approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 7.5mg, 15mg, 22.5mg and 40mg, Alembic Pharmaceuticals said in a BSE filing.
The approved abbreviated new drug application (ANDA) is the therapeutic equivalent to the reference listed drug product (RLD) Restoril Capsules.
Quoting IQVIA sales data, the company said, Temazepam capsules 7.5mg, 15mg, 22.5mg and 40mg had an estimated market size of USD 48 million for 12 months, ending December 2017.
The company's stock was trading at Rs 567 apiece, up 1.33 per cent, on the BSE.
Next Story
ADVERTISEMENT
